查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1449251

來那度胺市場、佔有率、規模、趨勢、行業分析報告：按類型、按應用、按最終用戶、按劑量、按地區、按細分市場、預測，2024-2032 年

Lenalidomide Market Share, Size, Trends, Industry Analysis Report, By Type (5mg,10mg,15mg,25mg); By Application; By End-User; By Dosage; By Region; Segment Forecast, 2024 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 118 Pages | 商品交期: 最快1-2個工作天內

價格

根據Polaris Market Research的最新研究，預計到2032年來那度胺的全球市場規模將達到156.7億美元。 該報告提供了對當前市場動態的詳細見解，並對未來市場成長進行了分析。

來那度胺的成長受到全球癌症患者數量不斷增加的強烈影響。 該藥物在治療多發性骨髓瘤、骨髓增生異常綜合症和淋巴瘤患者方面的高效性預計將推動市場需求。 製藥公司使用來那度胺作為品牌名稱來銷售來那度胺。

製藥公司為擴大來那度胺市場品牌覆蓋率而採取的越來越多舉措可能會刺激全球市場的成長，因為它可以提高藥物的可及性。 例如，2023年3月，Natco Pharma透過其經銷商Teva Pharmaceuticals宣佈在美國增加2.5mg和20mg規格的Revlimid最新版本。

此外，製藥公司正致力於來那度胺的市場開發，推動全球市場的擴張。 根據 Start on Therapeutics 報告 STAR-LLD，事實證明，注射到血液中的低劑量來那度胺是一些骨髓瘤患者的治療選擇。

血癌發生率的增加推動了市場對含有來那度胺的藥物的需求，並增強了其深層治療能力。 根據美國癌症協會2023年報告，美國預計將有609,820人死亡，新增1,958,310例癌症病例。 這一趨勢凸顯了增加來那度胺對患者的可及性的必要性。

製藥公司正在透過和解解決與來那度胺生產相關的專利問題，有助於增加該藥物在全球市場的供應。 例如，2023年，Sun Pharma 在與 Celgene Corporation 達成和解協議後，獲得了美國 FDA 的多規格仿製藥來那度胺膠囊的上市許可。 這將允許從 2026 年 1 月起在美國無限量生產，從而推動這種著名抗癌藥物在預測期內的供應。

來那度胺市場報告亮點

由於其靈活性，5mg 膠囊細分市場預計將在未來幾年實現最高成長。

由於來那度胺在多發性骨髓瘤治療中的出色表現，多發性骨髓瘤細分市場佔了最大的市場佔有率。

由於到醫院就診的癌症患者數量不斷增加，醫院部門預計將佔收入的更大佔有率。

由於患有癌症相關併發症的患者數量不斷增加，預計亞太地區將出現最快的增長。

目錄

第1章簡介

第 2 章執行摘要

第3章研究方法

第4章全球來那度胺市場洞察

  • 來那度胺 - 產業概況
  • 來那度胺市場動態
    • 推動者和機會
      • 多發性骨髓瘤的發生率增加
      • 加強研究來發展服用來那度胺的新方法
    • 抑制因素和挑戰
      • 藥物開發成本上升
  • 杵分析
  • 來那度胺產業趨勢
  • 價值鏈分析
  • COVID-19 感染的影響分析

第5章全球來那度胺市場，依類型

  • 主要發現
  • 簡介
  • 5毫克膠囊
  • 10毫克膠囊
  • 15毫克膠囊
  • 25毫克膠囊

第 6 章全球來那度胺市場，依應用劃分

  • 主要發現
  • 簡介
  • 多發性骨髓瘤 (MM)
  • 骨髓增生異常症候群 (MDS)
  • 淋巴瘤
  • 其他

第 7 章全球來那度胺市場，依最終用戶劃分

  • 主要發現
  • 簡介
  • 醫院
  • 癌症治療中心
  • 調查機構

第 8 章全球來那度胺市場（按劑量）

  • 主要發現
  • 簡介
  • 膠囊
  • 平板電腦

第 9 章全球來那度胺市場（依地區）

  • 主要發現
  • 簡介
    • 2019-2032 年來那度胺市場評估（按地區）
  • 來那度胺市場 - 北美
    • 北美：來那度胺市場，依類型，2019-2032 年
    • 北美：來那度胺市場，依劑量，2019-2032 年
    • 北美：來那度胺市場，依應用劃分，2019-2032 年
    • 北美：來那度胺市場，以最終用戶劃分，2019-2032 年
    • 來那度胺市場 - 美國
    • 來那度胺市場 - 加拿大
  • 來那度胺市場 - 歐洲
    • 歐洲：來那度胺市場（按類型），2019-2032 年
    • 歐洲：來那度胺市場，依劑量，2019-2032 年
    • 歐洲：來那度胺市場，依應用劃分，2019-2032 年
    • 歐洲：來那度胺市場，以最終用戶劃分，2019-2032 年
    • 來那度胺市場 - 英國
    • 來那度胺市場 - 法國
    • 來那度胺市場 - 德國
    • Lenali Domido 市場 - 義大利
    • 來那度胺市場 - 西班牙
    • 來那度胺市場 - 荷蘭
    • 來那度胺市場 - 俄羅斯
  • 來那度胺市場 - 亞太地區
    • 亞太地區：來那度胺市場，依類型，2019-2032 年
    • 亞太地區：來那度胺市場，依劑量，2019-2032 年
    • 亞太地區：來那度胺市場，依應用劃分，2019-2032 年
    • 亞太地區：來那度胺市場，以最終用戶劃分，2019-2032 年
    • 來那度胺市場 - 中國
    • 來那度胺市場-印度
    • 來那度胺市場 - 日本
    • 來那度胺市場 - 馬來西亞
    • 來那度胺市場-印度尼西亞
    • 來那度胺市場-韓國
  • 來那度胺市場 - 中東和非洲
    • 中東和非洲：來那度胺市場（按類型），2019-2032 年
    • 中東和非洲：來那度胺市場，按劑量，2019-2032 年
    • 中東和非洲：來那度胺市場，按應用劃分，2019-2032 年
    • 中東和非洲：來那度胺市場，按最終用戶劃分，2019-2032 年
    • 來那度胺市場-沙烏地阿拉伯
    • 來那度胺市場 - 南非
    • 來那度胺市場 - 以色列
    • 來那度胺市場 - 阿拉伯聯合大公國
  • 來那度胺市場 - 拉丁美洲
    • 拉丁美洲：來那度胺市場，依類型，2019-2032 年
    • 拉丁美洲：來那度胺市場，依劑量，2019-2032 年
    • 拉丁美洲：來那度胺市場，按應用劃分，2019-2032 年
    • 拉丁美洲：來那度胺市場，以最終用戶劃分，2019-2032 年
    • 來那度胺市場 - 墨西哥
    • 來那度胺市場 - 巴西
    • 來那度胺市場-阿根廷

第10章競爭態勢

  • 擴張與收購分析
    • 放大
    • 收購
  • 夥伴關係/協作/協議/揭露

第11章公司簡介

  • Ablynx（Belgium）
  • Actiza（India）
  • Celgene（US）
  • Celltrion（South Korea）
  • Dexa Medical（Indonesia）
  • Exova（UK）
  • LEO Pharma（Denmark）
  • Natco Pharma（India）
  • Toyama Chemical（Japan）
Product Code: PM4437

The global lenalidomide market size is expected to reach USD 15.67 billion by 2032, according to a new study by Polaris Market Research. The report "Lenalidomide Market Share, Size, Trends, Industry Analysis Report, By Type (5mg,10mg,15mg,25mg); By Application; By End-User; By Dosage; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The growth of lenalidomide is highly influenced by the increasing number of cancer cases worldwide. The higher efficiency of this drug in treating multiple myeloma, myelodysplastic syndromes, and lymphoma patients is anticipated to promote its demand in the marketplace. Pharmaceutical companies use Revlimid as a brand name in the marketing of lenalidomide.

The rising initiatives by pharmaceutical companies to expand their brand coverage in the lenalidomide market are likely to stimulate the growth of the global market, as they can enhance the accessibility of medicine. For instance, in March 2023, Natco Pharma unveiled the additional strengths of Revlimid in its latest version with 2.5 mg and 20 mg strengths in the United States through its marketing agent, Teva Pharmaceuticals.

Furthermore, pharmaceutical firms are engaging in development activities related to lenalidomide, driving the expansion of the global market. According to the Start on Therapeutics report, STAR-LLD, the infusion of lower-dose lenalidomide into the blood was demonstrated to be the optimal treatment over Revlimid in some myeloma patients.

The increasing incidence of blood cancer is facilitating the need for drugs, including lenalidomide, in the marketplace, driven by its profound ability to treat the disease. According to the American Cancer Society 2023 Report, in the United States, there will be 609,820 deaths caused by cancer, and the estimated number of new cases is 1,958,310. This trend is emphasizing the need to enhance the accessibility of lenalidomide for patients.

Pharmaceutical firms are resolving patent issues associated with the production of lenalidomide with the settlements, contributing to the increased supply of this drug in the global market. For instance, in 2023, Sun Pharma received approval from the USFDA to market generic lenalidomide capsules in several strengths after entering into a settlement agreement with Celgene Corporation. With this, it can produce an unlimited quantity after January 2026 in the U.S., fueling the supply of this prominent cancer drug during the forecast period.

Lenalidomide Market Report Highlights

5mg capsules segment is anticipated to witness the highest growth in the coming years due to its flexibility.

Multiple myeloma segment accounted for the largest market share owing to the prominent performance of lenalidomide in treating multiple myeloma.

Hospitals segment is projected to experience a larger revenue share due to the rising number of cancer patients consulting hospitals.

APAC is projected to register the fastest growth attributable to the increasing number of patients with cancer-based medical complications.

The global players include Ablynx, Actiza, Celgene, Celltrion, Dexa Medical, Exova, LEO Pharma, Natco Pharma, & Toyama Chemical.

Polaris Market Research has segmented the lenalidomide market report based on type, application, end-user, dosage, and region:

Lenalidomide, Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • 5mg Capsules
  • 10mg Capsules
  • 15mg Capsules
  • 25mg Capsules

Lenalidomide, Application Outlook (Revenue - USD Billion, 2019 - 2032)

  • Multiple myeloma (MM)
  • Myelodysplastic syndromes (MDS)
  • Lymphoma
  • Others

Lenalidomide, End-User Outlook (Revenue - USD Billion, 2019 - 2032)

  • Hospitals
  • Cancer Treatment Centers
  • Research Institutes

Lenalidomide, Dosage Outlook (Revenue - USD Billion, 2019 - 2032)

  • Capsules
  • Tablets

Lenalidomide, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Lenalidomide Market Insights

  • 4.1. Lenalidomide - Industry Snapshot
  • 4.2. Lenalidomide Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. The rising incidence of multiple myeloma
      • 4.2.1.2. The increasing research studies on developing new ways of having lenalidomide
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Higher costs of drug development
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Lenalidomide Industry Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Lenalidomide Market, by Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • 5.3. 5mg Capsules
    • 5.3.1. Global Lenalidomide Market, by 5mg Capsules, by Region, 2019-2032 (USD Billion)
  • 5.4. 10mg Capsules
    • 5.4.1. Global Lenalidomide Market, by 10mg Capsules, by Region, 2019-2032 (USD Billion)
  • 5.5. 15mg Capsules
    • 5.5.1. Global Lenalidomide Market, by 15mg Capsules, by Region, 2019-2032 (USD Billion)
  • 5.6. 25mg Capsules
    • 5.6.1. Global Lenalidomide Market, by 25mg Capsules, by Region, 2019-2032 (USD Billion)

6. Global Lenalidomide Market, by Application

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • 6.3. Multiple myeloma (MM)
    • 6.3.1. Global Lenalidomide Market, by Multiple myeloma (MM), by Region, 2019-2032 (USD Billion)
  • 6.4. Myelodysplastic syndromes (MDS)
    • 6.4.1. Global Lenalidomide Market, by Myelodysplastic syndromes (MDS), by Region, 2019-2032 (USD Billion)
  • 6.5. Lymphoma
    • 6.5.1. Global Lenalidomide Market, by Lymphoma, by Region, 2019-2032 (USD Billion)
  • 6.6. Others
    • 6.6.1. Global Lenalidomide Market, by Others, by Region, 2019-2032 (USD Billion)

7. Global Lenalidomide Market, by End-User

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • 7.3. Hospitals
    • 7.3.1. Global Lenalidomide Market, by Hospitals, by Region, 2019-2032 (USD Billion)
  • 7.4. Cancer Treatment Centers
    • 7.4.1. Global Lenalidomide Market, by Cancer Treatment Centers, by Region, 2019-2032 (USD Billion)
  • 7.5. Research Institutes
    • 7.5.1. Global Lenalidomide Market, by Research Institutes, by Region, 2019-2032 (USD Billion)

8. Global Lenalidomide Market, by Dosage

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • 8.3. Capsules
    • 8.3.1. Global Lenalidomide Market, by Capsules, by Region, 2019-2032 (USD Billion)
  • 8.4. Tablets
    • 8.4.1. Global Lenalidomide Market, by Tablets, by Region, 2019-2032 (USD Billion)

9. Global Lenalidomide Market, by Geography

  • 9.1. Key findings
  • 9.2. Introduction
    • 9.2.1. Lenalidomide Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 9.3. Lenalidomide Market - North America
    • 9.3.1. North America: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
    • 9.3.2. North America: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
    • 9.3.3. North America: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
    • 9.3.4. North America: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.3.5. Lenalidomide Market - U.S.
      • 9.3.5.1. U.S.: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.3.5.2. U.S.: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.3.5.3. U.S.: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.3.5.4. U.S.: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.3.6. Lenalidomide Market - Canada
      • 9.3.6.1. Canada: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.3.6.2. Canada: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.3.6.3. Canada: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.3.6.4. Canada: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • 9.4. Lenalidomide Market - Europe
    • 9.4.1. Europe: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
    • 9.4.2. Europe: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
    • 9.4.3. Europe: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
    • 9.4.4. Europe: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.4.5. Lenalidomide Market - UK
      • 9.4.5.1. UK: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.4.5.2. UK: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.4.5.3. UK: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.4.5.4. UK: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.4.6. Lenalidomide Market - France
      • 9.4.6.1. France: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.4.6.2. France: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.4.6.3. France: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.4.6.4. France: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.4.7. Lenalidomide Market - Germany
      • 9.4.7.1. Germany: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.4.7.2. Germany: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.4.7.3. Germany: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.4.7.4. Germany: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.4.8. Lenalidomide Market - Italy
      • 9.4.8.1. Italy: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.4.8.2. Italy: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.4.8.3. Italy: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.4.8.4. Italy: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.4.9. Lenalidomide Market - Spain
      • 9.4.9.1. Spain: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.4.9.2. Spain: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.4.9.3. Spain: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.4.9.4. Spain: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.4.10. Lenalidomide Market - Netherlands
      • 9.4.10.1. Netherlands: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.4.10.2. Netherlands: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.4.10.3. Netherlands: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.4.10.4. Netherlands: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.4.11. Lenalidomide Market - Russia
      • 9.4.11.1. Russia: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.4.11.2. Russia.: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.4.11.3. Russia: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.4.11.4. Russia: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • 9.5. Lenalidomide Market - Asia Pacific
    • 9.5.1. Asia Pacific: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
    • 9.5.2. Asia Pacific: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
    • 9.5.3. Asia Pacific: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
    • 9.5.4. Asia Pacific: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.5.5. Lenalidomide Market - China
      • 9.5.5.1. China: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.5.5.2. China.: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.5.5.3. China: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.5.5.4. China: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.5.6. Lenalidomide Market - India
      • 9.5.6.1. India: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.5.6.2. India.: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.5.6.3. India: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.5.6.4. India: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.5.7. Lenalidomide Market - Japan
      • 9.5.7.1. Japan: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.5.7.2. Japan.: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.5.7.3. Japan: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.5.7.4. Japan: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.5.8. Lenalidomide Market - Malaysia
      • 9.5.8.1. Malaysia: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.5.8.2. Malaysia.: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.5.8.3. Malaysia: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.5.8.4. Malaysia: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.5.9. Lenalidomide Market - Indonesia
      • 9.5.9.1. Indonesia: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.5.9.2. Indonesia.: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.5.9.3. Indonesia: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.5.9.4. Indonesia: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.5.10. Lenalidomide Market - South Korea
      • 9.5.10.1. South Korea: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.5.10.2. South Korea.: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.5.10.3. South Korea: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.5.10.4. South Korea: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • 9.6. Lenalidomide Market - Middle East & Africa
    • 9.6.1. Middle East & Africa: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
    • 9.6.2. Middle East & Africa: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
    • 9.6.3. Middle East & Africa: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
    • 9.6.4. Middle East & Africa: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.6.5. Lenalidomide Market - Saudi Arabia
      • 9.6.5.1. Saudi Arabia: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.6.5.2. Saudi Arabia: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.6.5.3. Saudi Arabia: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.6.5.4. Saudi Arabia: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.6.6. Lenalidomide Market - South Africa
      • 9.6.6.1. South Africa: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.6.6.2. South Africa: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.6.6.3. South Africa: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.6.6.4. South Africa: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.6.7. Lenalidomide Market - Israel
      • 9.6.7.1. Israel: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.6.7.2. Israel: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.6.7.3. Israel: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.6.7.4. Israel: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.6.8. Lenalidomide Market - UAE
      • 9.6.8.1. UAE: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.6.8.2. UAE: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.6.8.3. UAE: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.6.8.4. UAE: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • 9.7. Lenalidomide Market - Latin America
    • 9.7.1. Latin America: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
    • 9.7.2. Latin America: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
    • 9.7.3. Latin America: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
    • 9.7.4. Latin America: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.7.5. Lenalidomide Market - Mexico
      • 9.7.5.1. Mexico: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.7.5.2. Mexico: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.7.5.3. Mexico: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.7.5.4. Mexico: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.7.6. Lenalidomide Market - Brazil
      • 9.7.6.1. Brazil: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.7.6.2. Brazil: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.7.6.3. Brazil: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.7.6.4. Brazil: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.7.7. Lenalidomide Market - Argentina
      • 9.7.7.1. Argentina: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.7.7.2. Argentina: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.7.7.3. Argentina: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.7.7.4. Argentina: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)

10. Competitive Landscape

  • 10.1. Expansion and Acquisition Analysis
    • 10.1.1. Expansion
    • 10.1.2. Acquisitions
  • 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

  • 11.1. Ablynx (Belgium)
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Benchmarking
    • 11.1.4. Recent Development
  • 11.2. Actiza (India)
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Benchmarking
    • 11.2.4. Recent Development
  • 11.3. Celgene (US)
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Benchmarking
    • 11.3.4. Recent Development
  • 11.4. Celltrion (South Korea)
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Benchmarking
    • 11.4.4. Recent Development
  • 11.5. Dexa Medical (Indonesia)
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Benchmarking
    • 11.5.4. Recent Development
  • 11.6. Exova (UK)
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Benchmarking
    • 11.6.4. Recent Development
  • 11.7. LEO Pharma (Denmark)
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Benchmarking
    • 11.7.4. Recent Development
  • 11.8. Natco Pharma (India)
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Benchmarking
    • 11.8.4. Recent Development
  • 11.9. Toyama Chemical (Japan)
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Benchmarking
    • 11.9.4. Recent Development

List of Tables

  • Table 1 Global Lenalidomide Market, by Type, by Region, 2019-2032 (USD Billion)
  • Table 2 Global Lenalidomide Market, by Application, by Region, 2019-2032 (USD Billion)
  • Table 3 Global Lenalidomide Market, by End-User, by Region, 2019-2032 (USD Billion)
  • Table 4 Global Lenalidomide Market, by Dosage, by Region, 2019-2032 (USD Billion)
  • Table 5 Lenalidomide Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 6 North America: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 7 North America: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 8 North America: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 9 North America: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 10 U.S.: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 11 U.S.: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 12 U.S.: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 13 U.S.: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 14 Canada: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 15 Canada: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 16 Canada: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 17 Canada: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 18 Europe: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 19 Europe: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 20 Europe: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 21 Europe: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 22 Germany: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 23 Germany: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 24 Germany: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 25 Germany: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 26 France: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 27 France: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 28 France: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 29 France: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 30 UK: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 31 UK: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 32 UK: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 33 UK: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 34 Italy: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 35 Italy: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 36 Italy: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 37 Italy: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 38 Netherlands: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 39 Netherlands: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 40 Netherlands: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 41 Netherlands: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 42 Spain: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 43 Spain: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 44 Spain: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 45 Spain: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 46 Russia: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 47 Russia: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 48 Russia: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 49 Russia: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 50 Asia Pacific: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 51 Asia Pacific: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 52 Asia Pacific: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 53 Asia Pacific: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 54 China: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 55 China: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 56 China: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 57 China: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 58 Japan: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 59 Japan: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 60 Japan: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 61 Japan: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 62 India: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 63 India: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 64 India: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 65 India: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 66 Indonesia: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 67 Indonesia: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 68 Indonesia: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 69 Indonesia: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 70 Malaysia: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 71 Malaysia: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 72 Malaysia: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 73 Malaysia: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 74 South Korea: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 75 South Korea: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 76 South Korea: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 77 South Korea: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 78 Latin America: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 79 Latin America: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 80 Latin America: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 81 Latin America: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 82 Brazil: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 83 Brazil: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 84 Brazil: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 85 Brazil: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 86 Mexico: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 87 Mexico: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 88 Mexico: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 89 Mexico: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 90 Argentina: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 91 Argentina: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 92 Argentina: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 93 Argentina: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 94 Middle East & Africa: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 95 Middle East & Africa: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 96 Middle East & Africa: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 97 Middle East & Africa: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 98 UAE: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 99 UAE: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 100 UAE: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 101 UAE: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 102 Saudi Arabia: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 103 Saudi Arabia: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 104 Saudi Arabia: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 105 Saudi Arabia: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 106 South Africa: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 107 South Africa: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 108 South Africa: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 109 South Africa: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 110 Israel: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 111 Israel: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 112 Israel: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 113 Israel: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Lenalidomide Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Dosage
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Type
  • Figure 7. Global Lenalidomide Market, by Type, 2021 & 2030 (USD Billion)
  • Figure 8. Market by Dosage
  • Figure 9. Global Lenalidomide Market, by Dosage, 2021 & 2030 (USD Billion)
  • Figure 10. Market by Application
  • Figure 11. Global Lenalidomide Market, by Application, 2021 & 2030 (USD Billion)
  • Figure 12. Market by End-User
  • Figure 13. Global Lenalidomide Market, by End-User, 2021 & 2030 (USD Billion)